MEDESIS PHARMA (EPA:ALMDP) | WebDisclosure

Basculer en Français

10154	Companies
208595	Keywords
138705	Articles
110561	Press releases

Home
Companies
MEDESIS PHARMA

REGULATED PRESS RELEASE

published on 07/15/2024 at 16:55, 1 year 8 months ago

MEDESIS PHARMA : RAPPORT ANNUEL 2023
REGULATED PRESS RELEASE

published on 07/15/2024 at 08:00, 1 year 8 months ago

MEDESIS PHARMA: 2023 FULL-YEAR BUSINESS AND EARNINGS
REGULATED PRESS RELEASE

published on 07/15/2024 at 08:00, 1 year 8 months ago

MEDESIS PHARMA : ACTIVITÉS & RÉSULTATS ANNUELS 2023
REGULATED PRESS RELEASE

published on 06/03/2024 at 18:00, 1 year 9 months ago

MEDESIS PHARMA : Obtention d’un financement pour poursuivre l'analyse des résultats de la première phase d'essais cliniques de phase 2 pour le traitement de la maladie d’Alzheimer
REGULATED PRESS RELEASE

published on 03/19/2024 at 18:01, 2 years ago

Termination of the agreement between NICE and GREEN S.A. and Medesis Pharma
REGULATED PRESS RELEASE

published on 03/19/2024 at 18:01, 2 years ago

Medesis Pharma : Résiliation du contrat avec la société NICE & GREEN S.A.
REGULATED PRESS RELEASE

published on 01/29/2024 at 18:00, 2 years 2 months ago

MEDESIS PHARMA : Phase 2 clinical trial for the treatment of Alzheimer's disease - Completion of the 1st phase of double-blind treatment, with good patient retention and acceptance of the treatment
MEDESIS PHARMA successfully completes Phase 2 clinical trial for Alzheimer's disease, announces Nanolithium scientific publication, participation in BIOMED Forum, and a new cash contribution

Medesis Pharma Phase 2 Clinical Trial Alzheimer's Disease Nanolithium BIOMED Forum
REGULATED PRESS RELEASE

published on 01/29/2024 at 18:00, 2 years 2 months ago

MEDESIS PHARMA : Étude clinique de phase 2 pour le traitement de la maladie d’Alzheimer - Finalisation de la 1ère phase de traitement en double aveugle avec une bonne rétention des patients et une bonne acceptation du traitement
MEDESIS PHARMA annonce la finalisation de la 1ère phase de traitement en double aveugle de l'étude clinique de phase 2 pour le traitement de la maladie d'Alzheimer, une publication scientifique sur le NanoLithium, sa participation au BIOMED Forum le 30 janvier 2024, ainsi que la sécurisation d'une augmentation de capital d'environ 400 k€

Medesis Pharma Nanolithium Traitement Alzheimer Étude Clinique Phase 2 Sécurisation Augmentation De Capital
REGULATED PRESS RELEASE

published on 01/12/2024 at 17:45, 2 years 2 months ago

MEDESIS PHARMA CONFIRME SON ÉLIGIBILITÉ AU DISPOSITIF PEA-PME
MEDESIS PHARMA confirme son éligibilité au dispositif PEA-PME pour l'année 2024, permettant l'intégration de ses actions dans les portefeuilles PEA PME. La société développe des candidats médicaments en s'appuyant sur sa technologie propriétaire Aonys@ pour le traitement de maladies graves

PEA-PME Medesis Pharma Biotechnologie Pharmaceutique Candidats Médicaments Aonys@
REGULATED PRESS RELEASE

published on 01/12/2024 at 17:45, 2 years 2 months ago

MEDESIS PHARMA : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE S2 2023

Accesswire

Published on 04/02/2026 at 18:32, 2 hours 55 minutes ago

Datavault AI CEO Nathaniel Bradley to Present DataValue(R), DataScore(R), and Information Data Exchange(R) Technologies at XRP Tokyo 2026
Published on 04/02/2026 at 15:00, 6 hours 27 minutes ago

Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Published on 04/02/2026 at 14:40, 6 hours 47 minutes ago

Northfield Capital Completes Acquisition Of Additional Interest In Juno Corp. And Announces Issuance Of Class B Multiple Voting Shares
Published on 04/02/2026 at 14:30, 6 hours 57 minutes ago

Worksport Announces COR(TM) Portable Energy System Is Now Fully Certified, Including Key UL and CSA Approvals, for North American Retail and Commercial Distribution
Published on 04/02/2026 at 14:10, 7 hours 17 minutes ago

Side-by-Side Conference Hosts Close to 800 Participants in Malta to Advance Women's Health Care

View all ACCESSWIRE

EQS Group

Published on 04/02/2026 at 20:30, 57 minutes ago

Aquis Stock Exchange - Disciplinary Notice
Published on 04/02/2026 at 19:52, 1 hour 34 minutes ago

E-PANGO: Composition du capital au 31 mars 2026
Published on 04/02/2026 at 19:00, 2 hours 27 minutes ago

PATRIMOINE ET COMMERCE: INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF
Published on 04/02/2026 at 18:35, 2 hours 51 minutes ago

daydream Raises $15M Series A to Build the World's Best AI-Native Agency for SEO
Published on 04/02/2026 at 18:30, 2 hours 56 minutes ago

Avolta Publishes Invitation to its Annual General Meeting 2026

Les Echos

Published on 04/02/2026 at 18:39, 2 hours 47 minutes ago

Mersen: Disclosure of trading own shares
Published on 04/02/2026 at 18:39, 2 hours 47 minutes ago

Mersen : Déclaration des transactions sur actions propres
Published on 04/02/2026 at 18:30, 2 hours 57 minutes ago

Thales met à disposition son Document d’Enregistrement Universel 2025
Published on 04/02/2026 at 18:30, 2 hours 57 minutes ago

Thales makes available its Universal Registration Document 2025
Published on 04/02/2026 at 18:22, 3 hours 4 minutes ago

TF1 - Déclaration mensuelle des actions et droits de vote - Mars 2026

View all LES ECHOS COMFI WIRE